Surgical treatment of pancreatic endocrine tumors in MEN1 Machado MCC Figure 4 - Patient with bilateral liver metastases. After portal vein embolization of the right liver, an extended right hepatectomy was performed with enucleation of the left lobe metastases. usually associated with surgical resection. Liver transplan- tation may also be used in selected patients (27). CONCLUSION Surgical strategies applied to PETs/MEN1 may greatly differ from those used in patients with S-PETs. Clinical and genetic diagnosis of MEN1 should be performed or ruled out before surgery in all patients presenting with apparently sporadic PETs. The presurgical differential diagnosis between S-PETs and PETs/MEN1 will allow surgeons to choose the best surgical approach to each individual case, aiming to lower morbidity and mortality rates, or even obtain cure, in patients with PETs associated with MEN1. REFERENCES 1. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129(6):484–94. 2. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World J Surg. 1998;22(6):581–6, http://dx.doi.org/10.1007/s002689900438. 3. Lourenc¸o DM Jr, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JE, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008;159(3):259–74, http://dx.doi.org/10.1530/ EJE-08-0153. 4. Lourenc¸o DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25(11):2382–91, http://dx.doi.org/10.1002/jbmr.125. 5. Coutinho FL, Lourenc¸o DMJr, Toledo RA, GonDeur JE, Toledo SP. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf). 2010;72(4):462–8, http:// dx.doi.org/10.1111/j.1365-2265.2009.03672.x. 6. Lourenco DM Jr, Coutinho FL, Toledo RA, Gonc¸alves TD, Montenegro FL, Toledo SP. Biochemical, bone and renal patterns in hyperparathyr- oidism associated with multiple endocrine neoplasia type 1. Clinics. 2012;67(S1):99–108, http://dx.doi.org/10.6061/clinics/2012(Sup01)17. 7. Coutinho FL, Lourenco DM Jr, Toledo RA, Montenegro FL, Toledo SP. Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics. 2012;67(S1):169–72, http:// dx.doi.org/10.6061/clinics/2012(Sup01)28. 8. Toledo RA, Lourenco DM, Coutinho FL, Quedas E, Mackowiack I, Machado MC, et al. Novel MEN1 germline mutations in Brazilian 148 CLINICS 2012;67(S1):145-148 families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2007;67(3):377–84, http://dx.doi.org/10.1111/j.1365-2265.2007.02895.x. 9. Lourenc¸o DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics. 2007;62(4):465–76, http://dx.doi.org/10.1590/S1807-59322007000400014. 10. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga- DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10, http://dx.doi.org/10.1007/s00259-010-1512-3. 11. Machado MC, da Cunha JE, Jukemura J, Bacchella T, Penteado S, Abdo EE, et al. Insulinoma: diagnostic strategies and surgical treatment. A 22- year experience. Hepatogastroenterology. 2001;48(39):854–8. 12. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–55, http://dx.doi.org/ 10.1007/s00268-009-0290-1. 13. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al. Epidemiology data on 108 MEN1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243(2):265–72, http://dx.doi.org/10.1097/01.sla.0000197715.96762.68. 14. Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16(36):4519–25, http://dx.doi.org/10.3748/wjg.v16.i36.4519. 15. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7):1807– 43, http://dx.doi.org/10.1002/cncr.23648. 16. Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG, Whelan AJ, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5):637–45; discussion 645–7, http://dx.doi.org/10.1097/ 01.sla.0000124383.98416.8d. 17. Tonelli F, Fratini G, Nesi G, Tommasi MS, Batignani G, Falchetti A, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastri- nomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244(1):61– 70, http://dx.doi.org/10.1097/01.sla.0000218073.77254.62. 18. Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am. 1998;7(4):881–91. 19. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757–73, http://dx.doi.org/10.1097/01.sla.0000143252. 02142.3e. 20. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243(6):495–500, http:// dx.doi.org/10.1046/j.1365-2796.1998.00307.x. 21. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery. 1991;110(6):998–1004; discussion 1004–5. 22. Rasbach DA, van Heerden JA, Telander RL, Grant CS, Carney JA. Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome. Am J Med. 1985;78(2):337–42, http:// dx.doi.org/10.1016/0002-9343(85)90446-2. 23. Simon D, Starke A, Goretzki PE, Roeher HD. Reoperative surgery for organic hyperinsulinism: indications and operative strategy. World J Surg. 1998;22(7):666–71, http://dx.doi.org/10.1007/s002689900450. 24. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al. Guidelines for the management of gastroenteropancreatic neu- roendocrine tumours (including bronchopulmonary and thymic neo- plasms). Part I – general overview. Acta Oncol. 2004;43(7):617–25, http://dx.doi.org/10.1080/02841860410018575. 25. Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics. 2012;67(S1):109–12, http://dx.doi.org/10.6061/clinics/ 2012(Sup01)18. 26. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72, http://dx.doi.org/10.1016/S1470-2045(07)70410- 2. 27. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006;12(3):448–56, http://dx.doi.org/10.1002/lt.20702.